Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors. [PDF]
Commun Chem, 2023 Jiang X +17 more
europepmc +1 more source
Factors Influencing the Binding of HIV‐1 Protease Inhibitors: Insights from Machine Learning Models
ChemMedChem, Accepted Article.HIV‐1 protease inhibitors are crucial for antiviral therapies targeting acquired immunodeficiency syndrome (AIDS). Hundreds of HIV‐1 protease complexes with various ligands have been resolved and deposited in the Protein Data Bank. However, binding affinity measurements for these ligands are not always available.
Yaffa Shalit, Inbal Tuvi-Arad
wiley +1 more source
Kasmera, 2010 A prospective study was carried out to determine the effect of antiretroviral therapy on the lipid profile in a population of 50 patients with AIDS who received their first antiretroviral drug treatment in the HIV-AIDS clinic at the Maracaibo University ...
Isabel Soto +2 more
doaj
Suppression of Acute Viremia by Short-Term Postexposure Prophylaxis of Simian/Human Immunodeficiency Virus SHIV-RT-Infected Monkeys with a Novel Reverse Transcriptase Inhibitor (GW420867) Allows for Development of Potent Antiviral Immune Responses Resulting in Efficient Containment of Infection [PDF]
, 2000 Kazuyasu Mori +10 more
openalex +1 more source
Erratum: Author correction to 'Approved HIV reverse transcriptase inhibitors in the past decade' [Acta Pharmaceutica Sinica B 12 (2022) 1567-1590]. [PDF]
Acta Pharm Sin B, 2023 Li G, Wang Y, De Clercq E.
europepmc +1 more source
ChemMedChem, Accepted Article.We report the discovery and characterization of a novel series of 4,4‐difluoropiperidine etherbased dopamine D4 receptor antagonists. Structure‐activity relationship studies led to the identification of compound 14a, which displays exceptional binding affinity for the D4 receptor (Ki = 0.3 nM) and remarkable selectivity over other dopamine receptor ...
Saeedeh Saeedi +3 more
wiley +1 more source
The structure of HIV-1 reverse transcriptase complexed with an RNA pseudoknot inhibitor
, 1998 J. Jaeger
openalex +2 more sources
Editorial Response: Hyperlactatemia and Hepatic Steatosis as Features of Mitochondrial Toxicity of Nucleoside Analogue Reverse Transcriptase Inhibitors [PDF]
, 2000 Kees Brinkman
openalex +1 more source
Structure-based design of novel heterocycle-substituted ATDP analogs as non-nucleoside reverse transcriptase inhibitors with improved selectivity and solubility. [PDF]
Acta Pharm Sin B, 2023 Zhao LM +4 more
europepmc +1 more source
Clinical Pharmacology in Drug Development, EarlyView.Abstract Long‐acting (LA) cabotegravir 200‐mg/mL (CAB200) injections are approved for HIV‐1 prevention and as a complete LA HIV‐1 treatment regimen with rilpivirine. A high‐concentration suspension formulation, cabotegravir 400 mg/mL (CAB400‐D), was developed to enable less frequent dosing and self‐administration. This phase 1, double‐blind, randomized
Kelong Han +16 more
wiley +1 more source